Since 2017, several targeted therapies, including a BCL-2 inhibitor (venetoclax), FMS-like tyrosine kinase 3 (FLT3) inhibitors (gilteritinib, sorafenib, midostaurin, etc.)and isocitrate dehydrogenase (IDH) inhibitors (IDH1 inhibitor ivosidenib; IDH2 inhibitor enasidenib) [1, 3], have been approved for the treatment of patients with AML. Here, IDH2 is linked to acute myeloid leukemia.